A Multicenter, Randomized, Double-blind, Controlled, Phase III Study to Evaluate the Efficacy and Safety of IBI301 (Recombinant Chimeric Anti-CD20 Monoclonal Antibody) in Combination With CHOP Regimen Versus Rituximab in Combination With CHOP Regimen in Treatment-naive Patients With Diffuse Large B-cell Lymphoma (DLBCL)

Trial Profile

A Multicenter, Randomized, Double-blind, Controlled, Phase III Study to Evaluate the Efficacy and Safety of IBI301 (Recombinant Chimeric Anti-CD20 Monoclonal Antibody) in Combination With CHOP Regimen Versus Rituximab in Combination With CHOP Regimen in Treatment-naive Patients With Diffuse Large B-cell Lymphoma (DLBCL)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 20 Apr 2017

At a glance

  • Drugs Rituximab (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Vindesine
  • Indications Diffuse large B cell lymphoma
  • Focus Registrational; Therapeutic Use
  • Sponsors Innovent Biologics
  • Most Recent Events

    • 15 Sep 2016 According to an Innovent Biologics media release, status changed from not yet recruiting to recruiting.
    • 19 Aug 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top